Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses Recommendations of the Advisory Committee on Immunization Practices (ACIP) 2015.
On June 25, 2015, the Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination with live smallpox (vaccinia) vaccine (ACAM2000) for laboratory personnel who directly handle 1) cultures or 2) animals contaminated or infected with replication competent vaccinia virus, recombinant vaccinia viruses derived from replication competent vaccinia strains (i.e. those that are capable of causing clinical infection and producing infectious virus in humans) or other orthopoxviruses that infect humans (e.g. monkeypox, cowpox, and variola) (recommendation category: A, evidence type 2 [Box] Health care personnel (e.g. physicians and nurses) who currently treat or anticipate treating patients with vaccinia virus infections and whose contact with replication competent vaccinia viruses is limited to contaminated materials (e.g. dressings) and persons administering ACAM2000 smallpox vaccine who adhere to appropriate infection prevention measures can be offered vaccination with ACAM2000 (recommendation category: B, evidence type 2 [Box] These revised recommendations update the previous ACIP recommendations for nonemergency use of vaccinia virus smallpox vaccine for laboratory and health care personnel at risk for occupational exposure to orthopoxviruses (1) Since 2001, when the previous ACIP recommendations were developed, ACAM2000 has replaced Dryvax as the only smallpox vaccine licensed by the U.S. Food and Drug Administration (FDA) and available for use in the United States (2) These recommendations contain information on ACAM2000 and its use in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses.
MMWR. Morbidity and mortality weekly report